NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Menlo Therapeutics Inc. (NASDAQ: MNLO) resulting from allegations that Menlo may have issued materially misleading business information to the investing public.
On April 9, 2018, Menlo disclosed that its Phase 2 clinical trial of serlopitant for the treatment of pruritus in adults and adolescents with a history of atopic dermatitis did not meet its primary or key secondary efficacy endpoints. There was no statistically significant difference demonstrated between patients treated with serlopitant and patients treated with the placebo. On this news, Menlo’s stock fell $27.05 per share or over 76% to close at $8.17 on April 9, 2018.
Rosen Law Firm is preparing a class action lawsuit to recover losses suffered by Menlo investors. If you purchased shares of Menlo please visit the firm’s website at http://www.rosenlegal.com/cases-1387.html to join the class action. You may also contact Phillip Kim or Zachary Halper of Rosen Law Firm toll free at 866-767-3653 or via email at email@example.com or firstname.lastname@example.org.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 3 each year since 2013.
Attorney Advertising. Prior results do not guarantee a similar outcome.